Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Creaven

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Oncology Reports|January 31, 2004
Matrix metalloproteinase inhibitorsNithya Ramnath, Patrick J Creaven
Cancer Chemotherapy and Pharmacology|March 26, 2003
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumorsNithya Ramnath, Gary N Schwartz, Patrick Smith, et al.
Anti-Cancer Drugs|July 3, 2008
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II studyNithya Ramnath, Jihnhee Yu, Nikhil I Khushalani, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2007
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, William Brady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, Patrick F Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracilMilind M Javle, Shousong Cao, Farukh A Durrani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumorsMarwan G Fakih, Patrick J Creaven, Nithya Ramnath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumorsMarwan G Fakih, Donald L Trump, Josephia R Muindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumorsAlberto A Chiappori, S Gail Eckhardt, Ronald Bukowski, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Oncology Reports|January 31, 2004
Matrix metalloproteinase inhibitorsNithya Ramnath, Patrick J Creaven
Cancer Chemotherapy and Pharmacology|March 26, 2003
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumorsNithya Ramnath, Gary N Schwartz, Patrick Smith, et al.
Anti-Cancer Drugs|July 3, 2008
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II studyNithya Ramnath, Jihnhee Yu, Nikhil I Khushalani, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2007
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, William Brady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, Patrick F Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracilMilind M Javle, Shousong Cao, Farukh A Durrani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumorsMarwan G Fakih, Patrick J Creaven, Nithya Ramnath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumorsMarwan G Fakih, Donald L Trump, Josephia R Muindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumorsAlberto A Chiappori, S Gail Eckhardt, Ronald Bukowski, et al.
Pageof 1